CQDM: Innovation Catalyst

Catalyst of innovation for #biopharmaceutical companies

An economic stimulus for Quebec and Canada

CQDM - Key Elements of our Contribution to Canada's Economy

A Promising Project Portfolio
Over $309 Million in Fundraising

Since its inception in 2008, the biopharmaceutical research consortium that funds innovation has successfully gathered total contributions of over $274 million from:

– 9 of the world’s largest pharmaceutical companies: Merck, Pfizer, AstraZeneca, Boehringer Ingelheim, Eli Lilly Canada, GlaxoSmithKline, Janssen, Novartis Pharma Canada, Sanofi Canada, Servier, Roche, Takeda, and Amgen.
– The Ministry of Economy and Innovation (MEI) of the Government of Quebec.
– The Business-Led Networks of Centres of Excellence (BL-NCE) program of the Government of Canada.
– Its co-funding partners.

To date, CQDM has established 18 funding programs and launched 97 competitions.

Collaborative Research at its best

As of now, CQDM has:

– 123 exceptional research projects;
– Carried out by a network of over 1761 researchers, including 1,411 full-time equivalents (FTE) per year, with 383 graduate students trained;
– Across 132 different research institutions (50 public and 69 private);
– Involving 154 mentors from CQDM member pharmaceutical companies;
– For a total of $139 million committed to R&D by CQDM.

(*FTE: Full-Time Equivalent)

Promising Results

The results to date speak for themselves: technologies that accelerate drug discovery and significant socio-economic impacts, including:

– 85 projects successfully completed with 84.3% of milestones achieved.
– Pharmaceutical partners of CQDM committed to providing substantial additional contributions in several researchers’ labs to develop CQDM technologies.
– Support for the launch of 10 life sciences companies.
– $584 million in additional investments for researchers.

CQDM relies on over a decade of success!

Scroll to Top